DocGo (NASDAQ:DCGO) Price Target Cut to $2.50 by Analysts at Stifel Nicolaus

DocGo (NASDAQ:DCGO) had its price objective trimmed by Stifel Nicolaus from $4.00 to $2.50 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

DCGO has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of DocGo in a report on Monday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $3.00 price target on shares of DocGo in a report on Tuesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $3.00 price objective on shares of DocGo in a research report on Tuesday. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $2.50.

DocGo Trading Up 20.1%

Shares of NASDAQ DCGO opened at $0.78 on Tuesday. DocGo has a twelve month low of $0.60 and a twelve month high of $2.88. The firm has a 50-day moving average of $0.77 and a two-hundred day moving average of $1.02. The company has a market capitalization of $76.05 million, a price-to-earnings ratio of -0.42 and a beta of 0.95.

Institutional Trading of DocGo

Hedge funds and other institutional investors have recently modified their holdings of the company. P.A.W. Capital Corp raised its holdings in shares of DocGo by 60.0% in the second quarter. P.A.W. Capital Corp now owns 3,200,000 shares of the company’s stock valued at $5,024,000 after purchasing an additional 1,200,000 shares during the last quarter. Jefferies Financial Group Inc. grew its position in DocGo by 5.7% in the second quarter. Jefferies Financial Group Inc. now owns 2,144,456 shares of the company’s stock valued at $3,367,000 after purchasing an additional 115,000 shares in the last quarter. Empowered Funds LLC increased its stake in DocGo by 14.6% in the 4th quarter. Empowered Funds LLC now owns 138,306 shares of the company’s stock valued at $121,000 after buying an additional 17,607 shares during the last quarter. Squarepoint Ops LLC lifted its position in DocGo by 246.3% during the 4th quarter. Squarepoint Ops LLC now owns 94,511 shares of the company’s stock worth $83,000 after buying an additional 67,216 shares in the last quarter. Finally, Strs Ohio bought a new stake in DocGo during the 1st quarter worth about $76,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Key Stories Impacting DocGo

Here are the key news stories impacting DocGo this week:

• Positive Sentiment: Q4 revenue beat and market reaction — DocGo reported Q4 revenue of $74.9M, above consensus, and shares reportedly jumped (~15%) on the topline beat and upbeat commentary. Investing.com: DocGo shares surge
• Positive Sentiment: 2026 guidance and strategic review — management set 2026 revenue guidance of $290M–$310M, reiterated a path to profitability and said it is exploring strategic alternatives, which could unlock value or lead to a sale/transaction. Seeking Alpha: 2026 guidance & strategic alternatives
• Positive Sentiment: Analyst support — Cantor Fitzgerald reaffirmed an “overweight” rating with a $3 PT and Needham & Company reaffirmed a “buy” with a $3 PT, signaling continued institutional bullishness despite volatility. Benzinga: Cantor/Needham coverage
• Neutral Sentiment: Stifel revises target down — Stifel cut its price target from $4.00 to $2.50 but kept a “buy” rating, reducing near-term upside expectations while remaining constructive. Benzinga: Stifel lowers target
• Neutral Sentiment: Earnings call / transcripts available — management discussed the quarter, guidance and strategic alternatives on the Q4 2025 call; read the transcript for color on margin timing and capital allocation. MSN: Q4 2025 earnings call transcript
• Negative Sentiment: Large EPS miss and profitability pressure — DocGo reported a substantial GAAP loss for the quarter (wide of consensus) and negative margins/ROE, which underscore near-term profitability risks despite revenue growth in some areas. MarketBeat: Q4 results overview
• Negative Sentiment: YoY revenue drop in core operations — the company noted Q4 revenue declined versus prior year primarily due to the wind-down of a legacy business line, contributing to mixed investor reaction and continued execution risk. BusinessWire: Q4 & FY2025 results

About DocGo

DocGo, Inc is a U.S.-based integrated healthcare company that delivers on-demand and mobile healthcare services. The company’s business model centers on deploying customized medical clinics paired with a digital care platform to bring primary and acute care directly to patients. Through a combination of telemedicine and over-the-road medical units, DocGo addresses routine medical exams, chronic disease management, occupational health screenings, specialist consultations and urgent care interventions.

In addition to its mobile clinic fleet, DocGo’s digital platform offers 24/7 virtual care, facilitating remote consultations via video, phone or secure messaging.